← All trials
NCT01439958
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2012
- Primary completion
- Jul 31, 2013
- Completion date
- Dec 31, 2014
- First posted
- Sep 23, 2011
- Last posted
- Apr 14, 2015
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pari Pharma GmbHLead sponsor
- Ludwig Maximilians UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.